

Claims

1. A method for the treatment of a cancer comprising co-administering
5 an anti-tumor antibody and a cytokine to a subject in need thereof,
wherein the cytokine is administered continuously or repeatedly in a
low-dose form.
2. A method for the treatment of a cancer comprising co-
10 administering an anti-tumor antibody and a cytokine to a subject in
need thereof, wherein the method comprises:
(a) a first treatment stage comprising administering a low-dose
cytokine, and
(b) a second treatment stage comprising co-administering an anti-
15 tumor antibody and a low-dose cytokine.
3. The method of claim 1 or 2, wherein the low-dose cytokine
comprises a dose which is pharmaceutically effective in the
substantial absence of NIC CTC toxicity grade 3 or higher.
- 20 4. The method according to any one of claims 1-3 comprising a daily
administration of a low-dose cytokine.
5. The method of any one of claims 1-4 wherein the cytokine is
25 selected from interleukins and interferons.
6. The method of claim 5 wherein the cytokine is IL-2.
7. The method of claim 6 wherein the dose of IL-2 is in the range o f
30 from 1-10 MIU daily.
8. The method of claim 5 wherein the cytokine is IFN- α .

- 21 -

9. The method of claim 8 wherein the dose of IFN- α is in the range of from 1-10 MIU three times a week.
10. The method of any one of claims 1-9 wherein the cytokine is administered in a substantially constant dose during the treatment.
11. The method of any one of claims 1-9 wherein the cytokine is administered in a variable dose during the treatment.
12. The method of any one of claims 1-11 wherein the cytokine is administered subcutaneously.
13. The method of any one of claims 1-12 wherein the antitumor antibody is selected from antibodies directed against the MN (G250) antigen.
14. The method of any one of claims 1-13 wherein the antitumor antibody is a chimeric or humanized G250 antibody or a fragment thereof.
15. The method of any one of claims 1-14 wherein the antitumor antibody is administered in intervals of from 5-20 days.
16. The method of claim 2 wherein the first treatment stage comprises 5-20 days.
17. The method of claim 2 wherein the second treatment stage comprises 50-200 days.